ADVERTISEMENT

Home|Journals|Articles by Year|Audio Abstracts
 

Research Article

Open Vet J. 2025; 15(2): 901-910


Effects of probiotic supplementation on clinicopathological alterations in Barki sheep with mange

Asmaa A. Darwish.




Abstract

Background:
Ovine mange is a highly transmissible skin condition that typically results in significant economic losses.

Aim:
This research explored the clinicopathological alterations associated with mange in Barki sheep and evaluated the impact of integrating probiotics (ZAD) into the treatment protocol. Additionally, the study proposed diagnostic markers and indicators for assessing treatment prognosis.

Method:
Twenty healthy lambs (control group (CG)) and twenty lambs suffered from mange symptoms (confirmed by skin scrapings) in the diseased group (DG). DG was divided into two groups: the traditional group (TG) was injected once with 1ml/50 kg ivermectin 1% (Promectine, Invesa) subcutaneously injected + topical Zinc ointment, and the ZAD Group (ZG): received the same treatment + 5 ml/ head of ZAD orally, repeated daily for 3 weeks. Skin scraping was repeated weekly until complete curing in both groups. Blood samples were collected from CG, DG (before treatment), and TG and ZG (after recovery).

Results:
DG (compared to CG) showed a significant (P

Key words: Ovine Scabies, Clinicopathological changes, Probiotics, Hormones, Oxidative stress, MMPs






Full-text options


Share this Article


Online Article Submission
• ejmanager.com




ejPort - eJManager.com
Author Tools
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.